View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2016	Nov. 04, 2016
Document Information [Line Items]
Entity Registrant Name	Sucampo Pharmaceuticals, Inc.
Entity Central Index Key	0001365216
Trading Symbol	scmp
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		45,837,056
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 128,465,000	$ 108,284,000
Product royalties receivable	20,771,000	22,792,000
Accounts receivable, net	20,684,000	22,759,000
Restricted cash	25,213,000	55,218,000
Inventories	24,202,000	33,121,000
Prepaid expenses and other current assets	18,146,000	9,186,000
Total current assets	237,481,000	251,360,000
Long-lived assets	6,563,000	6,393,000
Intangible assets	134,886,000	130,315,000
Goodwill	73,022,000	60,937,000
In-process research and development		6,171,000
Deferred charge, non-current	1,400,000	1,400,000
Convertible note receivable	5,182,000
Other assets	1,030,000	605,000
Total assets	459,564,000	457,181,000
Current liabilities:
Accounts payable	7,869,000	11,213,000
Accrued expenses	14,380,000	10,886,000
Collaboration obligation	1,438,000	5,623,000
Income tax payable	16,587,000	6,507,000
Notes payable, current	21,730,000	39,083,000
Other current liabilities	4,805,000	14,815,000
Total current liabilities	66,809,000	88,127,000
Notes payable, non-current	196,984,000	213,277,000
Deferred revenue, non-current	913,000	1,088,000
Deferred tax liability, net	41,757,000	52,497,000
Other liabilities	8,291,000	15,743,000
Total liabilities	314,754,000	370,732,000
Commitments and contingencies (note 12)
Stockholders' equity:
Preferred stock, $0.01 par value; 5,000,000 shares authorized at September 30, 2016 and December 31, 2015; no shares issued and outstanding at September 30, 2016 and December 31, 2015	0	0
Additional paid-in capital	113,440,000	99,212,000
Accumulated other comprehensive income	54,339,000	13,412,000
Treasury stock, at cost; 3,009,942 shares at September 30, 2016 and December 31, 2015	(46,269,000)	(46,269,000)
Retained earnings	22,842,000	19,639,000
Total stockholders' equity	144,810,000	86,449,000
Total liabilities and stockholders' equity	459,564,000	457,181,000
Common Class A [Member]
Stockholders' equity:
Common stock value	458,000	455,000
Common Class B [Member]
Stockholders' equity:
Common stock value	$ 0	$ 0

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Treasury stock shares (in shares)	3,009,942	3,009,942
Common Class A [Member]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	270,000,000	270,000,000
Common stock, shares issued (in shares)	45,828,775	45,509,150
Common stock, shares outstanding (in shares)	45,828,775	45,509,150
Common Class B [Member]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	0	0
Common stock, shares outstanding (in shares)	0	0

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Product royalty revenue	$ 20,771	$ 19,328	$ 56,222	$ 51,209
Product sales revenue	31,554	11,022	86,538	36,678
Research and development revenue	3,172	2,714	9,971	7,468
Contract and collaboration revenue	2,376	384	4,301	2,457
Total revenues	57,873	33,448	157,032	97,812
Costs and expenses:
Costs of goods sold	15,586	5,286	59,278	18,656
Research and development	9,976	8,368	35,580	22,285
Impairment of in-process research and development	7,286		7,286
General and administrative	11,061	7,752	32,411	22,363
Selling and marketing	696	385	2,094	1,617
Total costs and expenses	44,605	21,791	136,649	64,921
Income from operations	13,268	11,657	20,383	32,891
Non-operating income (expense):
Interest income	31	62	67	155
Interest expense	(5,899)	(243)	(18,141)	(784)
Other income, net	8,102	87	5,216	1,947
Total non-operating income (expense), net	2,234	(94)	(12,858)	1,318
Income before income taxes	15,502	11,563	7,525	34,209
Income tax provision	(7,410)	(4,327)	(4,321)	(10,989)
Net income	$ 8,092	$ 7,236	$ 3,203	$ 23,220
Net income per share:
Basic (in dollars per share)	$ 0.19	$ 0.16	$ 0.08	$ 0.52
Diluted (in dollars per share)	$ 0.19	$ 0.16	$ 0.07	$ 0.51
Weighted average common shares outstanding:
Basic (in shares)	42,813	44,731	42,704	44,576
Diluted (in shares)	43,443	46,309	43,334	45,939
Comprehensive income
Net income	$ 8,092	$ 7,236	$ 3,203	$ 23,220
Other comprehensive income (expense):
Unrealized gain on pension benefit obligation	12	57	37	38
Unrealized gain (loss) on investments, net of tax effect		(6)		6
Foreign currency translation gain	4,635	264	40,890	102
Comprehensive income	$ 12,739	$ 7,551	$ 44,130	$ 23,366

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - 9 months ended Sep. 30, 2016 - USD ($)	Common Stock [Member] Common Class A [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2015	45,509,150			3,009,942
Balance at Dec. 31, 2015	$ 455,000	$ 99,212,000	$ 13,412,000	$ (46,269,000)	$ 19,639,000	$ 86,449,000
Stock-based compensation expense		5,445,000				5,445,000
Stock issued under exercise of stock options (in shares)	300,906
Stock issued under exercise of stock options	$ 3,000	1,659,000				1,662,000
Stock issued under employee stock purchase plan (in shares)	18,719
Stock issued under employee stock purchase plan		174,000				174,000
Windfall tax benefit from stock-based compensation		435,000				435,000
Unrealized gain on pension benefit obligation			37,000			37,000
Foreign currency translation gain			40,890,000			40,890,000
Treasury stock transfer		6,515,000				6,515,000
Net income					3,203,000	3,203,000
Balance (in shares) at Sep. 30, 2016	45,828,775			3,009,942
Balance at Sep. 30, 2016	$ 458,000	$ 113,440,000	$ 54,339,000	$ (46,269,000)	$ 22,842,000	$ 144,810,000

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income	$ 3,203,000	$ 23,220,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	37,873,000	433,000
Loss on disposal of property and equipment	535,000	77,000
Deferred tax provision	(16,571,000)	(2,828,000)
Deferred charge		221,000
Stock-based compensation	5,445,000	5,607,000
Amortization of premiums on investments		121,000
Unrealized currency translations	9,811,000	2,000
Shortfall from stock-based compensation	(25,000)
Windfall benefit from stock-based compensation	(460,000)
Transfer and assignment of licensing rights		(2,000,000)
Impairment of in-process research and development	7,286,000
Forgiveness of AMED deferred grant	(9,258,000)
Changes in operating assets and liabilities:
Product royalties receivable	2,021,000	(752,000)
Accounts receivable	3,526,000	(1,347,000)
Inventory	(2,000,000)	(296,000)
Prepaid and income taxes receivable and payable, net	(1,067,000)	(600,000)
Accounts payable	(4,094,000)	785,000
Accrued expenses	(2,414,000)	1,672,000
Accrued interest payable	(55,000)	227,000
Deferred revenue	(38,000)	(1,399,000)
Collaboration obligation	(4,185,000)	(448,000)
Other assets and liabilities, net	755,000	1,510,000
Net cash provided by operating activities	30,288,000	24,205,000
Cash flows from investing activities:
Purchases of investments	(250,000)	(39,775,000)
Proceeds from sales of investments		2,398,000
Maturities of investments		30,054,000
Transfer and assignment of licensing rights		2,000,000
Convertible note receivable	(5,000,000)
Changes in restricted cash	12,302,000	548,000
Payment of squeeze-out liability for non-tendering R-Tech shareholders	(7,668,000)
Purchases of property and equipment	(1,219,000)	(2,023,000)
Net cash used in investing activities	(1,835,000)	(6,798,000)
Cash flows from financing activities:
Payments of notes payable	(36,332,000)	(4,077,000)
Changes in restricted cash	17,676,000
Proceeds from exercise of stock options	1,662,000	4,829,000
Proceeds from employee stock purchase plan	174,000	74,000
Windfall benefit from stock-based compensation	460,000	1,600,000
Net cash (used in ) provided by financing activities	(16,360,000)	2,426,000
Effect of exchange rates on cash and cash equivalents	8,088,000	50,000
Net increase in cash and cash equivalents	20,181,000	19,883,000
Cash and cash equivalents at beginning of period	108,284,000	71,622,000
Cash and cash equivalents at end of period	$ 128,465,000	$ 91,505,000

Note 1 - Business Organization and Basis of Presentation

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Business Organization and Basis of Presentation

Description of the Business

Sucampo Pharmaceuticals, Inc., (Company) is a global biopharmaceutical company focused on developing, identifying, acquiring and bringing to market innovative medicines that meet unmet medical needs. Our primary focus areas are gastroenterology, ophthalmology, and oncology-related disorders.

The Company currently generates revenue mainly from product sales, product royalties, upfront and milestone payments, and reimbursements for development activities. The Company expects to continue to incur significant expenses for the next several years as the Company continues its research and development activities, seeks additional regulatory approvals and additional indications for approved products and other compounds and seeks strategic opportunities for in-licensing new products and product candidates.

AMITIZA

(lubiprostone) is being marketed for three gastrointestinal indications under the collaboration and license agreement (as amended in October 2014, the North America Takeda Agreement) with Takeda Pharmaceutical Company Limited (Takeda). These indications are chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) in adult women and opioid-induced constipation (OIC) in adults suffering from chronic non-cancer related pain. Under the North America Takeda Agreement, the Company is primarily responsible for clinical development activities, while Takeda is responsible for commercialization of AMITIZA in the United States (U.S.) and Canada. The Company and Takeda initiated commercial sales of AMITIZA in the U.S. for the treatment of CIC in April 2006, for the treatment of IBS-C in May 2008 and for the treatment of OIC in May 2013. Takeda is required to provide a minimum annual commercial investment during the current term of the North America Takeda Agreement and may reduce the minimum annual commercial investment when a generic equivalent enters the market. In October 2015, Health Canada approved AMITIZA for CIC in adults. In October 2014, the Company and Takeda executed amendments to the North America Takeda Agreement, which, among other things, extended the term of the North America Takeda Agreement beyond December 2020. During the extended term beginning in January 2021, Takeda and the Company will share the annual net sales revenue of the branded AMITIZA products. The Company also partnered with Par Pharmaceuticals, Inc. (Par) and Dr. Reddy’s Laboratories (DRL) in connection with the settlement of patent litigation in the U.S. related to our AMITIZA (lubiprostone) 8 mcg and 24 mcg soft gelatin capsule products. Under the agreement with Par, the Company granted Par a non-exclusive license to market Par’s generic version of lubiprostone 8 mcg and 24 mcg soft gelatin capsules in the U.S. for the indications approved for AMITIZA beginning January 1, 2021, or earlier under certain circumstances. Beginning on January 1, 2021, the Company and Par will split the gross profits of the licensed products sold during the term of the agreement, which continues until each of the related patents has expired. Under the agreement with DRL, the Company granted DRL a non-exclusive license to market DRL’s generic version of lubiprostone 8 mcg and 24 mcg soft gelatin capsules in the U.S. for the indications approved for AMITIZA beginning January 1, 2023, or earlier under certain circumstances. Beginning on January 1, 2023, DRL will pay to the Company 30% of the gross profits of the licensed products sold during the term of the agreement, which decreases over time and ends when all of the related patents have expired. Under the terms of the agreement with Par, DRL’s entry into the generic lubiprostone market will cause the Company’s share of gross profits from Par’s licensed products to decrease from 50% to 15%. In the event that either Par or DRL elect to launch an authorized generic form of lubiprostone, the Company has agreed to supply such product under the terms of a manufacturing and supply agreement at a negotiated price.

In Japan, AMITIZA is marketed under a license, commercialization and supply agreement (the Japan Mylan Agreement) that was transferred to Mylan, Inc. (Mylan) from Abbott Laboratories, Inc. (Abbott), as of February 2015, as part of Mylan’s acquisition of a product portfolio from Abbott. The Company received approval of its new drug application (NDA) for AMITIZA for the treatment of chronic constipation (CC), excluding constipation caused by organic diseases, from Japan’s Ministry of Health, Labour and Welfare (MHLW) in June 2012 and pricing approval in November 2012. AMITIZA is Japan’s only prescription medicine for CC. The Company did not experience any significant changes in the commercialization of AMITIZA in Japan as a result of the transfer of the Japan Mylan Agreement from Abbott to Mylan.

In May 2015, the Company entered into an exclusive license, development, commercialization and supply agreement (the China Gloria Agreement) with Harbin Gloria Pharmaceuticals Co., Ltd. (Gloria), for AMITIZA in the People’s Republic of China. Under the China Gloria Agreement, Gloria is responsible for all development activities and costs, as well as commercialization and regulatory activities, for AMITIZA in the People’s Republic of China. The Company will be the exclusive supplier of AMITIZA to Gloria at an agreed upon supply price. Upon entering into the China Gloria Agreement, the Company received an upfront payment of $1.0 million. In June 2015, the China Food and Drug Administration accepted an Investigational New Drug (IND) application for a pivotal trial of AMITIZA in patients with CIC; as a result, the Company received an additional payment of $500,000 from Gloria. In addition to the $1.5 million in payments received and recognized as revenue through June 2015, the Company is eligible to receive an additional payment for $1.5 million upon the occurrence of a specified regulatory or commercial milestone event.

In October 2014, the Company entered into an exclusive license, development, commercialization and supply agreement (the Global Takeda Agreement) for lubiprostone with Takeda, through which Takeda has the exclusive rights to further develop and commercialize AMITIZA in all global markets, except the U.S., Canada, Japan and the People’s Republic of China. Takeda became the marketing authorization holder in Switzerland in April 2015 and in the United Kingdom (U.K.), Austria, Belgium, Germany, Ireland, Netherlands, Luxembourg and Spain during 2016, and is expected to become the marketing authorization holder in Italy in the last quarter of 2016.

Before the execution of the Global Takeda Agreement, the Company retained full rights to develop and commercialize AMITIZA for the rest of the world’s markets outside of the U.S., Canada and Japan. In the U.K., the Company received approval in September 2012 from the Medicines and Healthcare Products Regulatory Agency (MHRA) for the use of AMITIZA to treat CIC. The Company made AMITIZA available in the U.K. in the fourth quarter of 2013. In July 2014, National Institute of Health and Care Excellence (NICE) published the technology appraisal guidance recommending the use of AMITIZA in the treatment of CIC and associated symptoms in adults who have failed laxatives. In January 2015, the Company successfully completed the European mutual recognition procedure (MRP) for AMITIZA for the treatment of CIC in select European countries, resulting in marketing authorizations in these countries.

In Switzerland, AMITIZA was approved to treat CIC in 2009. In 2012, the Company reached an agreement with the Bundesamt fur Gesundheit, (BAG), the Federal Office of Public Health in Switzerland, on a reimbursement price for AMITIZA in Switzerland, and began active marketing in the first quarter of 2013. In February 2014, the Company announced that the BAG revised several reimbursement limitations with which AMITIZA was first approved for reimbursement and inclusion in the Spezialitätenliste (SL) to allow all Swiss physicians to prescribe AMITIZA to patients who have failed previous treatments with at least two laxatives over a nine-month period. In July 2014, AMITIZA was approved for the treatment of OIC in chronic, non-cancer adult patients by the Swissmedic, the Swiss Agency for Therapeutic Products, and in October 2015, the BAG added this indication to the SL.

In October 2015, Takeda obtained approval of the clinical trial application (CTA) for AMITIZA for the treatment of CIC and IBS-C in Russia that was submitted in June 2015. In December 2015, a CTA was filed for AMITIZA for the treatment of CIC, IBS-C and OIC in Mexico and South Korea. Takeda initiated phase 3 registration trials in Russia in March 2016 and in South Korea and Mexico in May 2016. An NDA for the treatment of CIC, IBS-C, and OIC was submitted in Israel in June 2015 and approved in July 2016. An NDA for the same indications was submitted in Kazakhstan in December 2015. Additional NDA submissions in 2016 are planned in various other markets.

As part of the acquisition of R-Tech in October 2015, the Company acquired all rights to RESCULA, an ophthalmology product used to lower intraocular pressure. In the U.S., the Company ceased marketing RESCULA in the fourth quarter of 2014 and no product was made available after the March 2015 expiration date. In May 2015, the Company returned all licenses for unoprostone isopropyl to R-Tech. In June 2016, the Company completed the withdrawal of the marketing authorization for RESCULA in the U.S. RESCULA is being commercialized by Santen Pharmaceutical Co., Ltd in Japan, Dong-A Pharmaceutical, Co., Ltd in South Korea and Sinphar Pharmaceutical, Co., Ltd and Zuellig Pharma Inc. in Taiwan.

The Company’s other current clinical development programs include the following:

Lubiprostone Alternate Formulation

The Company has been developing an alternate formulation of lubiprostone for both adult and pediatric patients who are unable to take or do not tolerate capsules and for naso-gastric tube fed patients. Takeda has agreed to fund 100% of the costs, up to a cap, of this alternate formulation work and the Company expects to initiate a phase 3 trial of the alternate formulation of lubiprostone in adults in the second half of 2016 and, if the trial is successful, to file an NDA in the U.S. for the alternate formulation for adults in the second half of 2017.

Lubiprostone for Pediatric Functional Constipation

The phase 3 program required to support an application for marketing authorization of lubiprostone for pediatric functional constipation comprises four clinical trials. The first two trials, one of which was recently completed, test the soft gelatin capsule formulation of lubiprostone in patients 6 to 17 years of age. The first of these trials is a pivotal 12-week, randomized, placebo-controlled trial which was initiated in December 2013 and completed enrollment in April 2016. The second trial is a follow-on, long-term safety extension trial that was initiated in March 2014. In early November, the Company announced that the phase 3 trial of AMITIZA in pediatric functional constipation in children 6 to 17 years of age failed to achieve its primary endpoint of overall spontaneous bowel movement (SBM) response. The trial achieved statistical significance for some secondary endpoints, notably overall SBM frequency, straining, and stool consistency. In addition, in this study lubiprostone was well tolerated. The Company intends to review these results with the U.S. Food and Drug Administration (FDA) and other constituencies, and will announce next steps at the completion of this review. Additionally, after consultations with the FDA to better determine the doses and endpoints that should be studied, the phase 3 trial for the alternate formulation of lubiprostone described above will be followed in mid-2017 with a phase three program in children 6 months to 6 years of age using the alternate formulation. Takeda has agreed to fund 67% of the costs, up to a cap, of this pediatric functional constipation program.

VAP-1 Inhibitor RTU-1096

RTU-1096 is an oral compound recently under development for indications in auto-immune/inflammatory and immune-oncology diseases. In the first quarter of 2016, the Company completed a phase 1 trial in healthy individuals that evaluated the safety and pharmacokinetics of the compound. No significant safety issues were reported during the seven-day study. There was evidence of inhibition of systemic VAP-1 at all doses tested and the trial provided evidence of proof of mechanism

However, based on additional non-clinical data generated in the quarter, development of the compound has been discontinued.

VAP-1 Inhibitor RTU-009

RTU-009 is a pre-clinical stage, VAP-1 inhibitor that was planned to be studied in acute cerebral infarction. However, based on new non-clinical data and the decision to discontinue the development of RTU-1096, the development pathway has been revised to target chronic inflammatory conditions. The redirection of the RTU-009 program for chronic inflammatory conditions is just in the beginning stages and has no perceived value. However, the Company plans to complete IND-enabling studies, and thereafter initiate clinical-stage development if the compound meets additional pre-specified non-clinical development goals.

CPP-1X/Sulindac Combination Product

In January 2016, the Company entered into an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted the Company the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a phase 3 clinical trial being conducted by CPP for the treatment of familial adenomatous polyposis (FAP). Under the agreement with CPP, the Company has the exclusive option to license this product in North America. There are currently no approved treatments for FAP. The ongoing phase 3 study is a 150-patient, three-arm, double-blind, randomized trial of the combination agent and the single agent comparators. Enrollment in the study has completed, and results from a Phase 3 futility analysis are expected to be available in the 4th quarter of 2016 or early 2017. The trial is expected to conclude in 2018. More information regarding the Company’s arrangement with CPP is set forth in note 19 below.

Cobiprostone

In April 2016, the Company discontinued the development of cobiprostone for the treatment of proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD), based on its analysis of top-line data from a Phase 2a study. While cobiprostone was observed to have significant benefit in some of the secondary parameters of this exploratory study, the trial did not meet its primary endpoints. In July 2016, the Company discontinued the development of an oral spray formulation of cobiprostone for the prevention of oral mucositis in patients that are undergoing radio chemotherapy for head and neck cancer, based on the results of a pre-specified futility analysis of the Phase 2a study. The futility analysis indicated that the clinical benefit of cobiprostone was insufficient to support continuation of the study.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 11, 2016, as amended. The financial information as of September 30, 2016 and for the nine months ended September 30, 2016 and 2015 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.

The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG (SAG) based in Zug, Switzerland, through which the Company conducts certain of its worldwide and European operations; Sucampo Pharma, LLC (SPL) based in Osaka, Japan, through which the Company conducts its Asian operations; R-Tech Ueno, Ltd., based in Tokyo, Japan, through which the Company conducts manufacturing and certain development operations; Sucampo Pharma Americas LLC (SPA), based in Rockville, Maryland, through which the Company conducts its North American operations; and Sucampo Pharma Europe, Ltd. (SPE), based in Oxford, United Kingdom. All inter-company balances and transactions have been eliminated.

The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Note 2 - Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Summary of Significant Accounting Policies

Restricted Cash

As of September 30, 2016, restricted cash consisted of $25.2 million primarily related to the Credit Facility (see note 14); these funds will be held in a restricted account until at least $35 million of the Term Loans under the Credit Facility have been repaid or prepaid.

As of December 31, 2015, restricted cash consisted of $25.0 million related to the Credit Facility and $17.7 million related to the payment of the Ueno and Kuno Trust Notes (see note 13), which were settled on February 1, 2016, and $8.2 million related to the squeeze out of non-tendering R-Tech shareholders (see note 4), which was settled in January 2016.

Certain Risks, Concentrations and Uncertainties

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions. As of September 30, 2016 and December 31, 2015, approximately $1.8 million or 1.1%, and $5.9 million or 3.6%, respectively, of the Company’s cash, cash equivalents, and restricted cash were issued or insured by the United States government or other government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.

Revenues from Takeda, an unrelated party, accounted for 65.6% and 66.3% of the Company’s total revenues for the three months ended September 30, 2016 and 2015, respectively, and 65.7% and 60.4% for the nine months ended September 30, 2016 and 2015, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 82.6% and 78.1% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at September 30, 2016 and December 31, 2015, respectively.

Revenues from another unrelated party, Mylan, accounted for 29.6% and 30.8% of the Company’s total revenues for the three months ended September 30, 2016 and 2015, respectively, and 30.1% and 36.7% for the nine months ended September 30, 2016 and 2015, respectively. The Company depends significantly upon collaborations with Takeda and Mylan, and its activities may be impacted if these relationships are disrupted.

Fair Value of Financial Instruments

The carrying values of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable, convertible notes receivable, collaboration obligation and accrued expenses. The carrying amounts of the Credit Facility notes payable at September 30, 2016 and 2015 approximated fair value and are classified as a Level 2 instrument.

Variable Interest Entities

The Company performs initial and on-going evaluations of the entities with which it has variable interests, such as equity ownership, in order to identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest. Such entities are classified as variable interest entities (VIEs). If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE’s economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE. As of September 30, 2016, CPP, in which the Company held a variable interest, was determined to be a VIE. See note 19 for additional information.

Recent Accounting Pronouncements

In May 2014, the FASB issued authoritative guidance that sets forth a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The guidance was originally scheduled to be effective for annual reporting periods, including interim reporting periods within those periods, beginning after December 15, 2016, but in July 2015 the FASB voted to defer the effective date to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption is permitted, but not before the original effective date of December 15, 2016. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is currently evaluating the impact of this guidance on its results of operations, financial position and cash flows.

In April 2015

, the FASB issued ASU Number 2015-03,

Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs

(ASU 2015-03). ASU 2015-03 specifies that debt issuance costs related

to a note shall be reported in the balance sheet as a direct reduction from the face amount of the note. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. ASU 2015-03 had no effect on the Company’s results of operations or liquidity.

In November 2015, the FASB issued ASU No. 2015-17,

Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes

, (ASU 2015-17). This new guidance requires businesses to classify deferred tax liabilities and assets on their balance sheets as noncurrent. Under existing accounting, a business must separate deferred income tax liabilities and assets into current and noncurrent. ASU 2015-17 was issued as a way to simplify the way businesses classify deferred tax liabilities and assets on their balance sheets. Public companies must apply ASU 2015-17 to fiscal years beginning after December 15, 2016. Companies must follow the requirements for interim periods within those fiscal years, but early adoption at the beginning of an interim or annual period is allowed for all entities. The Company has elected to early adopt the guidance and has applied the guidance on a prospective basis. The adoption had no impact on the Company’s consolidated statements of operations and comprehensive income, changes in stockholders’ equity, and cash flows for the three and nine months ended September 30, 2016 and 2015.

In January 2016, the FASB issued Accounting Standards Update 2016-01,

Recognition and Measurement of Financial Assets and Financial Liabilities

, which requires that most equity investments be measured at fair value, with subsequent changes in fair value recognized in net income (other than those accounted for under equity method of accounting). This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.

In February 2016, the FASB issued Accounting Standards Update 2016-02,

Leases (Topic 842),

in which it provided new guidance related to accounting for leases. The new standard requires the recognition of assets and liabilities arising from lease transactions on the balance sheet and the disclosure of key information about leasing arrangements. Accordingly, a lessee will recognize a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. Both the asset and liability will initially be measured at the present value of the future minimum lease payments over the lease term. Subsequent measurement, including the presentation of expenses and cash flows, will depend on the classification of the lease as either finance or an operating lease. Initial costs directly attributable to negotiating and arranging the lease will be included in the asset. For leases with a term of 12 months or less, a lessee can make an accounting policy election by class of underlying asset to not recognize an asset and corresponding liability. Lessees will also be required to provide additional qualitative and quantitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. These disclosures are intended to supplement the amounts recorded in the financial statements and provide additional information about the nature of an organizations' leasing activities. The new standard is effective for fiscal years beginning after December 15, 2018 and interim periods within those years, with early adoption permitted. In transition, lessees are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The transition guidance also provides specific guidance for sale and leaseback transactions, build-to-suit leases and amounts previously recognized in accordance with the business combinations guidance for leases. The Company is currently evaluating its expected adoption method and the impact of this new standard on its consolidated financial statements and disclosures.

In March 2016, the FASB issued Accounting Standards Update 2016-09,

Improvements to Employee Share Based Payment Accounting

, which requires all of the tax effects related to share-based payments to be recorded through the income statement. The new guidance also removes the requirement to delay recognition of a windfall tax benefit until it reduces current taxes payable; instead, it is required to be recognized at the time of settlement, subject to normal valuation allowance considerations. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.

Note 3 - Net Income Per Share

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Earnings Per Share [Text Block]

Net Income per Share

Basic net income per share is computed by dividing net income by the sum of the weighted average class A common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average common shares and potential dilutive common shares outstanding.

The computation of net income per share for the three and nine months ended September 30, 2016 and 2015 is shown below:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands, except per share data)	2016		2015		2016		2015

Net income	$	8,092	$	7,236	$	3,203	$	23,220

Basic net income per share:
Weighted average class A common shares outstanding		42,813		44,731		42,704		44,576
Basic net income per share	$	0.19	$	0.16	$	0.08	$	0.52

Diluted net income per share:
Weighted average class A common shares outstanding		42,813		44,731		42,704		44,576
Assumed exercise of stock options under the treasury stock method		630		1,578		630		1,363
		43,443		46,309		43,334		45,939
Diluted net income per share	$	0.19	$	0.16	$	0.07	$	0.51

The following securities were excluded from the computation of diluted net income per share as their effect would have been anti-dilutive for the three and nine months ended September 30, 2016 and 2015:

	Three Months Ended September 30,				Nine Months Ended June 30,
(In thousands)	2016		2015		2016		2015
Employee stock options		2,410		273		2,410		884

Note 4 - Acquisition of R-Tech

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Business Acquisition, Integration, Restructuring and Other Related Costs [Text Block]

Acquisition of R-Tech

On October 20, 2015, the Company acquired approximately 98% of the outstanding shares of R-Tech Ueno, Ltd., a Japanese company (R-Tech). The Company acquired the remaining 2% of outstanding shares of R-Tech through a squeeze-out process under Japanese law on December 8, 2015. The total consideration for the acquisition was approximately $275 million. This transaction was accounted for under the acquisition method of accounting, with the Company as the acquirer. Under the acquisition method of accounting, the assets and liabilities of R-Tech were recorded as of the acquisition date at their respective fair values, and combined with those of the Company.

The final allocation of the purchase price based upon estimated fair value of assets acquired and liabilities assumed is as follows:

(In thousands)
Cash	$	62,097
Accounts receivable		8,299
Inventory		37,563
Other current assets		3,792
Property, plant and equipment		2,796
Other long term assets		449
Accounts payable and accrued liabilities		(11,598	)
Income tax payable		(5,025	)
Other liabilities, current		(3,282	)
Deferred tax liability, net		(63,365	)
Other liabilities, long term		(9,347	)
R-Tech shares of Sucampo stock (treasury stock)		43,956
Total fair value of tangible assets acquired and liabilities assumed		66,335
Acquired in-process research and development		6,200
Acquired intangible assets		134,600
Goodwill		61,618
Total purchase price	$	268,753

Total purchase price		268,753
Settlement of net receivable from pre-existing relationship		6,364
Total consideration	$	275,117
Acquisition, net of acquired cash		161,187
Acquired cash		62,097
Purchase of treasury stock		43,956
Squeeze out liability for non-tendering R-Tech shareholders		7,668
Other		209
Total consideration	$	275,117

The following unaudited pro forma information is presented as if the acquisition had occurred on January 1, 2015, and combines the historical results of operations of the Company and R-Tech for the three and nine months ended September 30, 2015.

	Three Months Ended September 30, 2015		Nine Months Ended September 30, 2015
(In thousands)
Pro forma revenue	$	43,529	$	129,529
Pro forma net income (loss)		1,301		(3,036	)

Note 5 - Segment Information

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Segment Information

The Company has one operating segment, which is the development and commercialization of pharmaceutical products.

Summarized product category and geographic information is shown in the tables below.

Product Category Information

Revenues for product categories are attributed based on the following categories.

Product royalty revenue represents royalty revenue earned on the net sales of AMITIZA in North America. Product sales revenue represents drug product net sales of AMITIZA in North America, Japan and Europe and drug product net sales of RESCULA in Japan. Research and development revenue represents funded development work primarily related to AMITIZA. Contract and collaboration revenue represents the amortization of up-front payments under the North America Takeda Agreement and release of the collaboration obligation under the Global Takeda Agreement (see note 15).

Company revenues by product category for the three and nine months ended September 30, 2016 and 2015 were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2016		2015		2016		2015
Product royalty revenue	$	20,771	$	19,328	$	56,222	$	51,209
Product sales revenue - AMITIZA		29,132		10,286		79,253		35,930
Product sales revenue - RESCULA		2,422		736		7,285		748
Research and development revenue		3,172		2,714		9,971		7,468
Contract and collaboration revenue		2,376		384		4,301		2,457
Total	$	57,873	$	33,448	$	157,032	$	97,812

Geographical Information

Revenues are attributable to countries based on the location of the customer. The Company operates a manufacturing facility in Japan that supplies products to customers as well as the Company’s subsidiaries in other countries. The sales from the manufacturing operations to other countries are included in the net sales of the country in which the manufacturing location is based. The intersegment portions of such sales are excluded to derive consolidated revenues. The Company’s country of domicile is the United States.

Company revenues by geographic location for the three and nine months ended September 30, 2016 and 2015 were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2016		2015		2016		2015
United States	$	34,911	$	22,919	$	98,073	$	59,850
Japan	$	19,839	$	10,295		54,004		35,952
Rest of the world	$	3,123	$	234		4,955		2,010
Total	$	57,873	$	33,448	$	157,032	$	97,812

The Company’s long-lived assets by geographic location where located on September 30, 2016 and December 31, 2015 were as follows:

(In thousands)	September 30, 2016		December 31, 2015
United States	$	3,192	$	3,105
Japan		3,333		3,232
Rest of the world		37		56
Total	$	6,563	$	6,393

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Note 6 - Fair Value Measurements

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Fair Value, Measurement Inputs, Disclosure [Text Block]

Fair Value measurements

The Company performs fair value measurements in accordance with the Financial Accounting Standards Board’s (FASB) guidance for fair value measurements and disclosures, which defines fair value as the exchange price that would be received for selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is established which requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company classifies its investments into the following categories based on the three levels of inputs used to measure fair value:

Level 1

: quoted prices in active markets for identical assets or liabilities,

Level 2

: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or

Level 3

: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company has elected the fair value option on its investment in CPP; as such, it is measured at fair value on a recurring basis. As of September 30, 2016, the fair value of the convertible note is $5.2 million using level 3 inputs (see note 19) provided by a valuation specialist using unobservable market level inputs and assumptions that include accrued interest and prepayment assumptions. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value can result from adjustments to the market level inputs and assumptions. The election was made upon the acquisition of the financial asset and cannot be revoked. The changes in fair value are recorded in current earnings within Other Income. As of September 30, 2016, there were no changes in the fair value of the note recorded in earnings related to the convertible note received from CPP. There were no other financial instruments measured at fair value on a recurring basis as of September 30, 2016.

Note 7 - Restructuring

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Restructuring and Related Activities Disclosure [Text Block]

Restructuring

In December 2015, the Company adopted a plan to restructure certain of its operations and to consolidate certain functions in the Company’s corporate headquarters located in Rockville, Maryland and in the Company’s Japanese subsidiaries. During the nine months ended September 30, 2016, the Company recorded pretax charges of approximately $1.9 million in connection with these restructuring activities. The restructuring plan primarily included headcount reductions in connection with the ongoing integration of R-Tech (see note 4). These costs are reflected within operating expenses and are detailed below:

	Incurred during the nine months ended September 30, 2016
(In thousands)
Termination benefits	$	1,809
Asset impairments		86
Contract and other costs		24
Total	$	1,919

As of September 30, 2016, a restructuring accrual of $1.0 million for termination benefits was included in accrued liabilities. The following table summarizes the accrued restructuring costs at September 30, 2016.

(In thousands)	Termination Benefits			Facility Related			Contract & Other Costs			Total
Balance at December 31, 2014	$	-		$	-		$	-		$	-
Expenses incurred		953			-			-			953
Amounts paid		(102	)		-			-			(102	)
Balance at December 31, 2015	$	851		$	-		$	-		$	851
Expenses incurred	$	1,809		$	86		$	24		$	1,919
Amounts paid		(1,669	)		(86	)		(24	)		(1,779	)
Foreign currency translation adjustment		14			-			-			14
Balance at September 30, 2016	$	1,005		$	-		$	-		$	1,005

The Company expects to record additional restructuring charges in the final quarter of 2016 related to this program and in connection with the ongoing integration of R-Tech. The Company has incurred total restructuring charges under this plan of $2.9 million through September 30, 2016.

Note 8 - Inventory

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Inventory Disclosure [Text Block]

Inventory

Inventories are valued under a weighted average costing method and are stated at the lower of cost or net realizable value. Inventories consist of raw materials, work-in-process and finished goods. The Company’s inventories include the direct purchase cost of materials and supplies and manufacturing overhead costs. In connection with the acquisition of R-Tech, all inventory held by R-Tech was stepped-up in fair value to $37.6 million as of the acquisition date. As of September 30, 2016 and December 31, 2015, the remaining balance of inventory step-up was zero and $14.3 million, respectively.

Inventory consisted of the following at September 30, 2016 and December 31, 2015:

(In thousands)	September 30, 2016		December 31, 2015
Raw materials	$	2,370	$	5,554
Work in process		20,380		26,926
Finished goods		1,452		641
Total	$	24,202	$	33,121

Note 9 - Intangible Assets

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

Intangible Assets

Intangible assets by major class consisted of the following as of September 30, 2016 and December 31, 2015:

	September 30, 2016					December 31, 2015
(In thousands)	Weighted average life (in months)		Carrying amount			Weighted average life (in months)		Carrying amount
Amortized intangible assets
Patent and license rights		63	$	10,513			72	$	10,513
Manufacturing know-how		68		134,600			76		134,600
Accumulated amortization				(27,382	)				(8,463	)
Impairment losses				(5,651	)				(5,651	)
Foreign currency translation adjustments				22,806					(684	)
Total amortized intangible assets			$	134,886				$	130,315

Unamortized intangible assets
In-process research and development			$	-				$	6,171
Goodwill				73,022					60,937
Total unamortized intangible assets			$	73,022				$	67,108

Total intangible assets			$	207,908				$	197,423

The changes in intangible assets for the nine months ended September 30, 2016 are as follows:

(In thousands)		Intangibles			Goodwill		In-process research & development
Balance at December 31, 2015	$	130,315		$	60,937	$	6,171
Additions/(Impairments)		-			455		(7,286	)
Amortization		(18,907	)		-		-
Foreign currency translation adjustment		23,478			11,630		1,115
Balance at September 30, 2016	$	134,886		$	73,022	$	-

During the quarter ended September 30, 2016, the Company discontinued its VAP-1 Inhibitor RTU-1096 development program and changed the indication for its VAP-1 Inhibitor RTU-009 program. The Company considered the discontinuance and change in indication as a potential indicator of impairment of the related in-process research and development (IPR&D) asset. Accordingly, the Company performed an interim assessment, and as a result, recorded an impairment charge of $7.3 million during the quarter ended September 30, 2016, which represented the entire carrying value of the IPR&D asset. This charge is classified in the Company’s statement of operations as impairment of in-process research and development.

Note 10 - Accrued Expenses and Other Current Liabilities

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

10.

Accrued Expenses and Other Current Liabilities

Accrued expenses consisted of the following at September 30, 2016 and December 31, 2015:

(In thousands)	September 30, 2016		December 31, 2015
Research and development costs	$	8,142	$	3,843
Employee compensation		3,447		4,860
Restructuring		1,005		851
Legal, consulting & other professional expenses		821		428
Other accrued expenses		965		904
Total	$	14,380	$	10,886

Other current liabilities consisted of the following at September 30, 2016 and December 31, 2015:

(In thousands)	September 30, 2016		December 31, 2015
Indirect taxes payable	$	3,029	$	5,963
Squeeze out liability for non-tendering R-Tech shareholders		249		7,668
Deferred revenue		813		676
Other liabilities		714		508
Total	$	4,805	$	14,815

Note 11 - Other Liabilities

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Other Liabilities Disclosure [Text Block]

11.

Other Liabilities

Other liabilities consisted of the following at September 30, 2016 and December 31, 2015:

(In thousands)	September 30, 2016		December 31, 2015
Deferred grants	$	750	$	9,604
Unrecognized tax benefits		3,694		3,061
Deferred leasehold incentive		1,618		1,715
Defined benefit obligation		972		949
Other liabilities		1,257		414
Total	$	8,291	$	15,743

At December 31, 2015, deferred grants consisted of a $9.3 million grant from the Japan Agency for Medical Research & Development (AMED), for use in developing unoprostone-related medicine for Retinitis Pigmentosa (see below), and a $300,000 government grant from Montgomery County, Maryland related to the move of the Company’s headquarters. Both grants may have to be repaid if certain conditions are not met.

Under its arrangement with AMED, R-Tech received ¥1.05 billion to support the development of unoprostone. This grant would be repayable in full if R-Tech terminated the development of unoprostone for commercial or other reasons, but only in part if such termination was due to scientific failure of the compound. R-Tech discontinued the development of unoprostone in early 2016. At the time of the Company’s acquisition of R-Tech, AMED’s position, on which we relied when accounting for this liability at the time of the R-Tech acquisition, was that the full amount of the grant would be repayable by R-Tech because such termination was for convenience, rather than due to a scientific failure of the compound. In September 2016, however, AMED agreed to waive the repayment of all but approximately ¥105 million (approximately $1.0 million) of the grant, representing 10% of the funds received by R-Tech from AMED through the end of March 2014. The Company recognized approximately $9.3 million in other income for the three and nine months ended September 30, 2016 because of this grant forgiveness.

Note 12 - Commitments and Contingencies

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

12.

Commitments and Contingencies

Operating Leases

The Company leases office space in the United States, Switzerland and Japan under operating leases through 2027. Total future minimum, non-cancelable lease payments under operating leases are as follows:

(In thousands)	September 30, 2016
2016	$	576
2017		1,186
2018		1,323
2019		1,048
2020		974
2021		3,188
Total minimum lease payments	$	8,295

Rent expense for all operating leases was $650,000 and $482,000 for the three months ended September 30, 2016 and 2015, respectively, and $2.0 million and $1.1 million for the nine months ended September 30, 2016 and 2015, respectively.

Numab Commitment

In July 2016, Numab repaid all outstanding amounts under its loan from Zurcher Kantonalbank, which was guaranteed by the Company under the Numab Agreement (see note 13). As a result, the Company’s liability associated with the Numab Agreement guarantee has been released.

Note 13 - Related Party Transactions

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

13.

Related Party Transactions

R-Tech Ueno, Ltd.

Before the R-Tech acquisition on October 20, 2015, R-Tech was a related party through common ownership. Prior to the R-Tech acquisition, the Company did not own manufacturing facilities. Instead, the Company contracted with R-Tech as the sole manufacturer of the Company’s products to produce AMITIZA and RESCULA. The Company had entered into multiple exclusive supply arrangements with R-Tech and had granted to R-Tech the exclusive right to manufacture and supply AMITIZA and other products and compounds to the Company to meet its commercial and clinical requirements.

The Company received upfront, development and milestone payments under these agreements totaling $9.0 million through October 20, 2015. The Company recorded the following expenses under all of its agreements with R-Tech for the three and nine months ended September 30, 2015:

(In thousands)	Three Months Ended September 30, 2015		Nine Months Ended September 30, 2015
Clinical supplies	$	106	$	143
Other research and development services		258		347
Commercial supplies		4,860		18,038
	$	5,224	$	18,528

The Company recognized $356,000 and $829,000 of revenue relating to its agreements with R-Tech for the three and nine months ended September 30, 2015, respectively, which was recorded as contract and collaboration revenue in the accompanying condensed consolidated statements of operations and comprehensive income.

Numab AG

In September 2011, the Company entered into a loan guarantee and development agreement (the Numab Agreement) with Numab AG (Numab). Under the terms of the Numab Agreement, the Company provided Numab with up to CHF 5.0 million as collateral and served as guarantor for a loan to Numab from a third party, Zurcher Kantonalbank. Following the payment of the first success fee during the first quarter of 2013, this amount was reduced to CHF 2.2 million, or approximately $2.2 million, as of December 31, 2015. As of December 31, 2015, collateral of CHF 2.2 million had been deposited by the Company and Numab had utilized CHF 1.5 million of its loan facility, or approximately $1.5 million. At December 31, 2015, the Company had recorded a guarantee liability of $202,000 in collateral callable to meet a potential loan default by Numab.

In July 2016, Numab repaid all outstanding amounts under its loan from Zurcher Kantonalbank, which was guaranteed by the Company under the Numab Agreement. As a result, the Company’s liability associated with the Numab Agreement guarantee has been released, and all deposited collateral returned.

Subordinated Unsecured Promissory Notes

In connection with the SAG acquisition in 2010, the Company issued subordinated unsecured promissory notes (Notes) to the Ueno Trust and Kuno Trust, former shareholders of SAG. The Ueno Trust and Kuno Trust are considered related parties. Each of the Notes was issued with an initial principal balance of approximately $25.9 million, or approximately $51.9 million in the aggregate. The interest rate for the Notes was the sum of the London Interbank Offered Rate, or LIBOR, plus 4.0%, and was reset on December 1, 2015 to 4.7%. On February 1, 2016, the Notes were paid in full.

Note 14 - Credit Facility and Notes Payable

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Debt Disclosure [Text Block]

14.

Credit Facility and Notes Payable

On October 16, 2015, the Company entered into a Credit Agreement (Credit Facility) with Jefferies Financing LLC. Term Loans under the Credit Facility bear interest, at the Company’s option, at the Adjusted Eurodollar Rate plus 7.25% or the Adjustable Base Rate plus 6.25%. The average interest rate on the notes payable for the nine months ending September 30, 2016 was 8.43%. The Company was in compliance with all covenants under the Credit Facility as of September 30, 2016.

The Company’s debt is subject to the fair value disclosure requirements as discussed in note 2. The carrying amounts of the notes payable at September 30, 2016 and 2015 approximated fair value and are classified as a Level 2 instrument.

Note 15 - Collaboration Obligation

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Collaborative Arrangement Disclosure [Text Block]

15.

Collaboration Obligation

Due to the signing of the Global Takeda Agreement, the Company received an upfront payment from Takeda of $14.0 million in 2014, of which the Company is obligated to reimburse Takeda for the first $6.0 million in developmental expenses incurred by Takeda. As of September 30, 2016 and December 31, 2015, the collaboration obligation was $1.4 million and $5.6 million, respectively.

Note 16 - Collaboration and License Agreements

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Collaborative and License Arrangement Disclosure [Text Block]

16.

Collaboration and License Agreements

North America Takeda Agreement

The following table summarizes the cash streams and related revenue recognized or deferred under the North America Takeda Agreement for the nine months ended September 30, 2016:

(In thousands)	Amount Deferred at December 31, 2015		Cash Received for the Nine Months Ended September 30, 2016		Revenue Recognized for the Nine Months Ended September 30, 2016		Change in Receivables for the Nine Months Ended September 30, 2016			Foreign Currency Effects for the Nine Months Ended September 30, 2016		Amount Deferred at September 30, 2016

Product royalty revenue	$	-	$	58,027	$	56,005	$	(2,022	)	$	-	$	-

Product sales revenue	$	-	$	34,382	$	32,240	$	(501	)	$	1,641	$	-

Research and development revenue:
Reimbursement of research and development expenses	$	-	$	9,378	$	9,964	$	586		$	-	$	-

Collaboration revenue:
Up-front payment associated with the Company's obligation to participate in joint committees	$	736	$	-	$	110	$	-		$	-	$	626

Japan Mylan Agreement

The following table summarizes the cash streams and related revenue recognized or deferred under the Japan Mylan Agreement for the nine months ended September 30, 2016:

(In thousands)	Amount Deferred at December 31, 2015		Cash Received for the Nine Months Ended September 30, 2016		Revenue Recognized for the Nine Months Ended September 30, 2016		Change in Receivables for the Nine Months Ended September 30, 2016		Foreign Currency Effects for the Nine Months Ended September 30, 2016			Amount Deferred at September 30, 2016

Product sales revenue	$	-	$	49,276	$	49,053	$	2,122	$	(2,344	)	$	-

Collaboration revenue:
Up-front payment associated with the Company's obligation to participate in joint committees	$	416	$	-	$	29	$	-	$	95		$	482

Japan Santen Agreement

The Company has recorded RESCULA product sales revenue for the three and nine months ended September 30, 2016 of approximately $2.3 million and $7.1 million, respectively, under its distribution agreement with Santen Pharmaceutical Co., Ltd. for the commercialization of RESCULA in Japan.

Note 17 - Stock Option Plans

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

17.

Stock Option Plans

A summary of employee stock option activity for the nine months ended September 30, 2016 under the Company’s Amended and Restated 2001 Stock Incentive Plan is presented below:

2001 Stock Incentive Plan	Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2015		37,400		$	10.00
Options exercised		(20,400	)		10.00
Options expired		(17,000	)		10.00
Options outstanding, September 30, 2016		-					-	$	-
Options exercisable, September 30, 2016		-					-	$	-
Options vested and expected to vest, September 30, 2016		-					-	$	-

A summary of employee stock option activity for the nine months ended September 30, 2016 under the Company’s Amended and Restated 2006 Stock Incentive Plan is presented below:

2006 Stock Incentive Plan	Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2015		4,440,608		$	9.37
Options granted		1,266,050			13.60
Options exercised		(280,506	)		5.20
Options forfeited		(90,918	)		13.68
Options expired		(59,365	)		14.53
Options outstanding, September 30, 2016		5,275,869			10.49		8.07	$	14,796,907
Options exercisable, September 30, 2016		2,060,515			8.45		6.96	$	9,134,458
Options vested and expected to vest, September 30, 2016		2,061,303			8.45		6.96	$	9,140,683

The weighted average grant date fair value of options granted during the nine months ended September 30, 2016 and the year ended December 31, 2015 was $7.10 and $9.45, respectively.

A summary of employee stock option activity for the nine months ended September 30, 2016 under the Company’s 2016 Equity Incentive Plan, or the 2016 Plan, is presented below:

2016 Equity Incentive Plan	Shares		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2015		-	$	-
Options granted		41,164		13.55
Options outstanding, September 30, 2016		41,164		13.55		1.12	$	9,926
Options exercisable, September 30, 2016		-		-		-	$	-
Options vested and expected to vest, September 30, 2016		-		-		-	$	-

A summary of employee restricted stock units activity for the nine months ended September 30, 2016 under the Company’s 2016 Plan is presented below:

2016 Equity Incentive Plan	Shares		Weighted Average Grant-Date Fair Value
Nonvested Restricted Stock Units, December 31, 2015		-	$	-
Restricted Stock Units granted		63,700		12.29
Restricted Stock Units vested		-
Restricted Stock Units forfeited		-
Nonvested Restricted Stock Units, September 30, 2016		63,700		12.29

Employee Stock Purchase Plan

Under the Company’s 2006 Employee Stock Purchase Plan, the Company received $46,262 and $36,324 upon employees’ purchase of 4,932 and 2,502 shares of class A common stock during the three months ended September 30, 2016 and 2015, respectively, and $174,572 and $74,414 upon employees’ purchase of 18,719 and 5,442 shares of class A common stock during the nine months ended September 30, 2016 and 2015, respectively.

Accumulated Other Comprehensive Income

The following table details the accumulated other comprehensive income activity for the nine months ended September 30, 2016:

(In thousands)		Foreign currency translation adjustments		Unrealized income on investments, net of tax effect		Unrealized income (loss) on pension benefit obligation			Accumulated other comprehensive income
Balance January 1, 2016	$	14,243	$	42	$	(873	)	$	13,412
Other comprehensive income before reclassifications		40,890		-		37			40,927
Amounts reclassified from accumulated other comprehensive loss		-		-		-			-
Balance September 30, 2016	$	55,133	$	42	$	(836	)	$	54,339

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Note 18 - Income Taxes

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Income Tax Disclosure [Text Block]

18.

Income Taxes

The provision for income taxes is based upon the estimated annual effective tax rates for the year applied to the current period income before tax plus the tax effect of any significant unusual items, discrete events or changes in tax law. The Company’s operating subsidiaries are exposed to statutory effective tax rates ranging from zero to approximately 40%. Fluctuations in the distribution of pre-tax income among the Company’s operating subsidiaries can lead to fluctuations of the effective tax rate in the condensed consolidated financial statements. In the three-month periods ended September 30, 2016 and 2015, the actual effective tax rates were 47.8% and 37.4%, respectively, and for the nine-month periods ended September 30, 2016 and 2015, the actual effective tax rates were 57.4% and 32.1%, respectively.

The Company assesses uncertain tax positions in accordance with ASC 740-10

Accounting for Uncertainties in Tax

. As of September 30, 2016, the Company’s net unrecognized tax benefits totaled approximately $3.4 million. Of this balance, $1.8 million would favorably impact the Company’s effective tax rate in the periods if they are recognized. Management has not identified any material uncertain tax positions that are reasonably likely to be released during the next 12 months due to lapse of statutes of limitations or settlements with tax authorities.

The Company conducts business globally and, as a result, files numerous consolidated and separate income tax returns in the U.S., Switzerland and Japan, as well as in various other state and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities throughout the world. Currently tax years 2011 to 2015 remain open and subject to examination in the major tax jurisdictions in which tax returns are filed. The tax years 2009-2011 were examined by the U.S. tax authorities and resulted in no tax adjustments.

Note 19 - Investment in CPP

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Collaborative and License Arrangement Disclosure [Text Block]

16.

Collaboration and License Agreements

North America Takeda Agreement

The following table summarizes the cash streams and related revenue recognized or deferred under the North America Takeda Agreement for the nine months ended September 30, 2016:

(In thousands)	Amount Deferred at December 31, 2015		Cash Received for the Nine Months Ended September 30, 2016		Revenue Recognized for the Nine Months Ended September 30, 2016		Change in Receivables for the Nine Months Ended September 30, 2016			Foreign Currency Effects for the Nine Months Ended September 30, 2016		Amount Deferred at September 30, 2016

Product royalty revenue	$	-	$	58,027	$	56,005	$	(2,022	)	$	-	$	-

Product sales revenue	$	-	$	34,382	$	32,240	$	(501	)	$	1,641	$	-

Research and development revenue:
Reimbursement of research and development expenses	$	-	$	9,378	$	9,964	$	586		$	-	$	-

Collaboration revenue:
Up-front payment associated with the Company's obligation to participate in joint committees	$	736	$	-	$	110	$	-		$	-	$	626

Japan Mylan Agreement

The following table summarizes the cash streams and related revenue recognized or deferred under the Japan Mylan Agreement for the nine months ended September 30, 2016:

(In thousands)	Amount Deferred at December 31, 2015		Cash Received for the Nine Months Ended September 30, 2016		Revenue Recognized for the Nine Months Ended September 30, 2016		Change in Receivables for the Nine Months Ended September 30, 2016		Foreign Currency Effects for the Nine Months Ended September 30, 2016			Amount Deferred at September 30, 2016

Product sales revenue	$	-	$	49,276	$	49,053	$	2,122	$	(2,344	)	$	-

Collaboration revenue:
Up-front payment associated with the Company's obligation to participate in joint committees	$	416	$	-	$	29	$	-	$	95		$	482

Japan Santen Agreement

CPP [Member]

Notes to Financial Statements

Collaborative and License Arrangement Disclosure [Text Block]

19.

Investment in CPP

On January 9, 2016, the Company entered into a Securities Purchase Agreement and an Option and Collaboration Agreement with Cancer Prevention Pharmaceuticals (CPP) for the development and commercialization of CPP-1X/sulindac combination.

The Company made a $5.0 million loan to CPP in exchange for a convertible note. The convertible note bears interest at the rate of 5% per annum and matures on January 31, 2019 unless earlier converted or prepaid. The convertible note is automatically convertible into securities of CPP, subject to certain limitations, in the event CPP consummates a future financing with aggregate proceeds at least $10.0 million, exclusive of any investment by the Company, whether through a public offering or a private offering (a Qualified Financing). Depending on the timing of the Qualified Financing, the convertible note will automatically convert into the same securities issued in the Qualified Financing at a 10% to 20% discount to the lowest issuance price of the securities in the Qualified Financing.

The Company has also agreed to purchase up to $5.0 million of CPP’s securities in any such Qualified Financing. CPP filed a Registration Statement on Form S-1 with the Securities and Exchange Commission in December 2015

for the sale of its common stock in an initial public offering. If completed, the initial public offering would be considered a Qualified Financing. The Company expects that the convertible note will convert into shares of CPP’s common stock in its initial public offering at a 10% discount to the public offering price and that the Company will purchase $5.0 million of shares of CPP common stock in that offering.

Under the terms of an Option and Collaboration Agreement, CPP granted the Company the sole option to acquire an exclusive license to commercialize CPP-1X/Sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP). Target enrollment in the study was achieved in April 2016 and the trial is expected to conclude in 2018. The Company will pay CPP an option fee of $7.5 million, payable in two tranches. The first tranche of $3.0 million was paid in January 2016 and was recorded as research and development expense. The second tranche of $4.5 million is due upon achievement of certain results of the ongoing feasibility study, which are expected in early 2017. CPP will complete the ongoing Phase 3 trial under the oversight of a joint steering committee between CPP and the Company. Upon exercise of its exclusive option, the Company would negotiate an exclusive license to develop and commercialize the product in North America for all indications. In connection with the exercise of the option right, the subsequent execution of a license agreement and the development and commercialization of the product, the Company would be obligated to pay CPP up to an aggregate of $190.0 million of specified clinical development and sales milestones. Under the terms of the license, the Company and CPP would share equally in net profits from the sale of licensed products.

The Company has elected the fair value option on the convertible note received from CPP due to the nature of the financial characteristics of the investment. As of September 30, 2016, the fair value of the convertible note is $5.2 million using level 3 inputs.

CPP is considered to be a VIE with respect to the Company. It has been determined that the power to direct the activities that most significantly impact CPP’s economic performance is held by the board of directors of CPP. The Company does not have a representative on CPP’s board and does not have the right to appoint or elect such a representative. Therefore, the Company is not the primary beneficiary of CPP, and the entity is not consolidated with the financial statements of the Company. The company’s maximum exposure to loss as a result of its involvement with CPP is $5.2 million as of September 30, 2016, which is the investment in the convertible security of $5.2 million. As of June 30, 2016, CPP had total assets of $7.1 million and total liabilities of $20.5 million.

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2016
Accounting Policies [Abstract]
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash As of September 30, 2016, restricted cash consisted of $25.2 million primarily related to the Credit Facility (see note 14); these funds will be held in a restricted account until at least $35 million of the Term Loans under the Credit Facility have been repaid or prepaid. As of December 31, 2015, restricted cash consisted of $25.0 million related to the Credit Facility and $17.7 million related to the payment of the Ueno and Kuno Trust Notes (see note 13), which were settled on February 1, 2016, and $8.2 million related to the squeeze out of non-tendering R-Tech shareholders (see note 4), which was settled in January 2016.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Certain Risks, Concentrations and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions. As of September 30, 2016 and December 31, 2015, approximately $1.8 million or 1.1%, and $5.9 million or 3.6%, respectively, of the Company’s cash, cash equivalents, and restricted cash were issued or insured by the United States government or other government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits. Revenues from Takeda, an unrelated party, accounted for 65.7% and 66.3% of the Company’s total revenues for the three months ended September 30, 2016 and 2015, respectively, and 65.6% and 60.4% for the nine months ended September 30, 2016 and 2015, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 82.6% and 78.1% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at September 30, 2016 and December 31, 2015, respectively. Revenues from another unrelated party, Mylan, accounted for 30.1% and 30.8% of the Company’s total revenues for the three months ended September 30, 2016 and 2015, respectively, and 29.6% and 36.7% for the nine months ended September 30, 2016 and 2015, respectively. The Company depends significantly upon collaborations with Takeda and Mylan, and its activities may be impacted if these relationships are disrupted.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying values of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable, convertible notes receivable, collaboration obligation and accrued expenses. The carrying amounts of the Credit Facility notes payable at September 30, 2016 and December 31, 2015 approximated fair value and are classified as a Level 2 instrument.
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	Variable Interest Entities The Company performs initial and on-going evaluations of the entities with which it has variable interests, such as equity ownership, in order to identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest. Such entities are classified as variable interest entities (VIEs). If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE’s economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE. As of September 30, 2016, CPP, in which the Company held a variable interest, was determined to be a VIE. See note 19 for additional information.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the FASB issued authoritative guidance that sets forth a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The guidance was originally scheduled to be effective for annual reporting periods, including interim reporting periods within those periods, beginning after December 15, 2016, but in July 2015 the FASB voted to defer the effective date to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption is permitted, but not before the original effective date of December 15, 2016. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is currently evaluating the impact of this guidance on its results of operations, financial position and cash flows. In April 2015 , the FASB issued ASU Number 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (ASU 2015-03). ASU 2015-03 specifies that debt issuance costs related to a note shall be reported in the balance sheet as a direct reduction from the face amount of the note. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. ASU 2015-03 had no effect on the Company’s results of operations or liquidity. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes , (ASU 2015-17). This new guidance requires businesses to classify deferred tax liabilities and assets on their balance sheets as noncurrent. Under existing accounting, a business must separate deferred income tax liabilities and assets into current and noncurrent. ASU 2015-17 was issued as a way to simplify the way businesses classify deferred tax liabilities and assets on their balance sheets. Public companies must apply ASU 2015-17 to fiscal years beginning after December 15, 2016. Companies must follow the requirements for interim periods within those fiscal years, but early adoption at the beginning of an interim or annual period is allowed for all entities. The Company has elected to early adopt the guidance and has applied the guidance on a prospective basis. The adoption had no impact on the Company’s consolidated statements of operations and comprehensive income, changes in stockholders’ equity, and cash flows for the three and nine months ended September 30, 2016 and 2015. In January 2016, the FASB issued Accounting Standards Update 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities , which requires that most equity investments be measured at fair value, with subsequent changes in fair value recognized in net income (other than those accounted for under equity method of accounting). This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases (Topic 842), in which it provided new guidance related to accounting for leases. The new standard requires the recognition of assets and liabilities arising from lease transactions on the balance sheet and the disclosure of key information about leasing arrangements. Accordingly, a lessee will recognize a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. Both the asset and liability will initially be measured at the present value of the future minimum lease payments over the lease term. Subsequent measurement, including the presentation of expenses and cash flows, will depend on the classification of the lease as either finance or an operating lease. Initial costs directly attributable to negotiating and arranging the lease will be included in the asset. For leases with a term of 12 months or less, a lessee can make an accounting policy election by class of underlying asset to not recognize an asset and corresponding liability. Lessees will also be required to provide additional qualitative and quantitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. These disclosures are intended to supplement the amounts recorded in the financial statements and provide additional information about the nature of an organizations' leasing activities. The new standard is effective for fiscal years beginning after December 15, 2018 and interim periods within those years, with early adoption permitted. In transition, lessees are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The transition guidance also provides specific guidance for sale and leaseback transactions, build-to-suit leases and amounts previously recognized in accordance with the business combinations guidance for leases. The Company is currently evaluating its expected adoption method and the impact of this new standard on its consolidated financial statements and disclosures. In March 2016, the FASB issued Accounting Standards Update 2016-09, Improvements to Employee Share Based Payment Accounting , which requires all of the tax effects related to share-based payments to be recorded through the income statement. The new guidance also removes the requirement to delay recognition of a windfall tax benefit until it reduces current taxes payable; instead, it is required to be recognized at the time of settlement, subject to normal valuation allowance considerations. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.

Note 3 - Net Income Per Share (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands, except per share data)	2016		2015		2016		2015

Net income	$	8,092	$	7,236	$	3,203	$	23,220

Basic net income per share:
Weighted average class A common shares outstanding		42,813		44,731		42,704		44,576
Basic net income per share	$	0.19	$	0.16	$	0.08	$	0.52

Diluted net income per share:
Weighted average class A common shares outstanding		42,813		44,731		42,704		44,576
Assumed exercise of stock options under the treasury stock method		630		1,578		630		1,363
		43,443		46,309		43,334		45,939
Diluted net income per share	$	0.19	$	0.16	$	0.07	$	0.51

Schedule of Potentially Dilutive Securities [Table Text Block]

Note 4 - Acquisition of R-Tech (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

(In thousands)
Cash	$	62,097
Accounts receivable		8,299
Inventory		37,563
Other current assets		3,792
Property, plant and equipment		2,796
Other long term assets		449
Accounts payable and accrued liabilities		(11,598	)
Income tax payable		(5,025	)
Other liabilities, current		(3,282	)
Deferred tax liability, net		(63,365	)
Other liabilities, long term		(9,347	)
R-Tech shares of Sucampo stock (treasury stock)		43,956
Total fair value of tangible assets acquired and liabilities assumed		66,335
Acquired in-process research and development		6,200
Acquired intangible assets		134,600
Goodwill		61,618
Total purchase price	$	268,753

Total purchase price		268,753
Settlement of net receivable from pre-existing relationship		6,364
Total consideration	$	275,117
Acquisition, net of acquired cash		161,187
Acquired cash		62,097
Purchase of treasury stock		43,956
Squeeze out liability for non-tendering R-Tech shareholders		7,668
Other		209
Total consideration	$	275,117

Business Acquisition, Pro Forma Information [Table Text Block]

	Three Months Ended September 30, 2015		Nine Months Ended September 30, 2015
(In thousands)
Pro forma revenue	$	43,529	$	129,529
Pro forma net income (loss)		1,301		(3,036	)

Note 5 - Segment Information (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

Revenue from External Customers by Products and Services [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2016		2015		2016		2015
Product royalty revenue	$	20,771	$	19,328	$	56,222	$	51,209
Product sales revenue - AMITIZA		29,132		10,286		79,253		35,930
Product sales revenue - RESCULA		2,422		736		7,285		748
Research and development revenue		3,172		2,714		9,971		7,468
Contract and collaboration revenue		2,376		384		4,301		2,457
Total	$	57,873	$	33,448	$	157,032	$	97,812

Revenue from External Customers by Geographic Areas [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2016		2015		2016		2015
United States	$	34,911	$	22,919	$	98,073	$	59,850
Japan	$	19,839	$	10,295		54,004		35,952
Rest of the world	$	3,123	$	234		4,955		2,010
Total	$	57,873	$	33,448	$	157,032	$	97,812

Long-lived Assets by Geographic Areas [Table Text Block]

(In thousands)	September 30, 2016		December 31, 2015
United States	$	3,192	$	3,105
Japan		3,333		3,232
Rest of the world		37		56
Total	$	6,563	$	6,393

Note 7 - Restructuring (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

Restructuring and Related Costs [Table Text Block]

	Incurred during the nine months ended September 30, 2016
(In thousands)
Termination benefits	$	1,809
Asset impairments		86
Contract and other costs		24
Total	$	1,919

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

null

Note 8 - Inventory (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Inventory, Current [Table Text Block]

(In thousands)	September 30, 2016		December 31, 2015
Raw materials	$	2,370	$	5,554
Work in process		20,380		26,926
Finished goods		1,452		641
Total	$	24,202	$	33,121

Note 9 - Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Intangible Assets and Goodwill [Table Text Block]

	September 30, 2016					December 31, 2015
(In thousands)	Weighted average life (in months)		Carrying amount			Weighted average life (in months)		Carrying amount
Amortized intangible assets
Patent and license rights		63	$	10,513			72	$	10,513
Manufacturing know-how		68		134,600			76		134,600
Accumulated amortization				(27,382	)				(8,463	)
Impairment losses				(5,651	)				(5,651	)
Foreign currency translation adjustments				22,806					(684	)
Total amortized intangible assets			$	134,886				$	130,315

Unamortized intangible assets
In-process research and development			$	-				$	6,171
Goodwill				73,022					60,937
Total unamortized intangible assets			$	73,022				$	67,108

Total intangible assets			$	207,908				$	197,423

Schedule of Changes in Intangible Assets and Goodwill [Table Text Block]

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">(In thousands)</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Intangibles</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Goodwill</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In-process research & development</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-size: 10pt">Balance at December 31, 2015</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">130,315</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">60,937</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">6,171</td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 10pt">Additions/(Impairments)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">455</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">(7,286</td> <td style="font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 10pt">Amortization</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">(18,907</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Foreign currency translation adjustment</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23,478</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,630</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,115</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance at September 30, 2016</td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">134,886</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">73,022</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"> </td> </tr> </table></div>

Note 10 - Accrued Expenses and Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

(In thousands)	September 30, 2016		December 31, 2015
Research and development costs	$	8,142	$	3,843
Employee compensation		3,447		4,860
Restructuring		1,005		851
Legal, consulting & other professional expenses		821		428
Other accrued expenses		965		904
Total	$	14,380	$	10,886

(In thousands)	September 30, 2016		December 31, 2015
Indirect taxes payable	$	3,029	$	5,963
Squeeze out liability for non-tendering R-Tech shareholders		249		7,668
Deferred revenue		813		676
Other liabilities		714		508
Total	$	4,805	$	14,815

Note 11 - Other Liabilities (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

Other Noncurrent Liabilities [Table Text Block]

(In thousands)	September 30, 2016		December 31, 2015
Deferred grants	$	750	$	9,604
Unrecognized tax benefits		3,694		3,061
Deferred leasehold incentive		1,618		1,715
Defined benefit obligation		972		949
Other liabilities		1,257		414
Total	$	8,291	$	15,743

Note 12 - Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

(In thousands)	September 30, 2016
2016	$	576
2017		1,186
2018		1,323
2019		1,048
2020		974
2021		3,188
Total minimum lease payments	$	8,295

Note 13 - Related Party Transactions (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

(In thousands)	Three Months Ended September 30, 2015		Nine Months Ended September 30, 2015
Clinical supplies	$	106	$	143
Other research and development services		258		347
Commercial supplies		4,860		18,038
	$	5,224	$	18,528

Note 16 - Collaboration and License Agreements (Tables)

9 Months Ended

Sep. 30, 2016

Mylan [Member]

Notes Tables

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

(In thousands)	Amount Deferred at December 31, 2015		Cash Received for the Nine Months Ended September 30, 2016		Revenue Recognized for the Nine Months Ended September 30, 2016		Change in Receivables for the Nine Months Ended September 30, 2016		Foreign Currency Effects for the Nine Months Ended September 30, 2016			Amount Deferred at September 30, 2016

Product sales revenue	$	-	$	49,276	$	49,053	$	2,122	$	(2,344	)	$	-

Collaboration revenue:
Up-front payment associated with the Company's obligation to participate in joint committees	$	416	$	-	$	29	$	-	$	95		$	482

Takeda [Member]

Notes Tables

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

(In thousands)	Amount Deferred at December 31, 2015		Cash Received for the Nine Months Ended September 30, 2016		Revenue Recognized for the Nine Months Ended September 30, 2016		Change in Receivables for the Nine Months Ended September 30, 2016			Foreign Currency Effects for the Nine Months Ended September 30, 2016		Amount Deferred at September 30, 2016

Product royalty revenue	$	-	$	58,027	$	56,005	$	(2,022	)	$	-	$	-

Product sales revenue	$	-	$	34,382	$	32,240	$	(501	)	$	1,641	$	-

Research and development revenue:
Reimbursement of research and development expenses	$	-	$	9,378	$	9,964	$	586		$	-	$	-

Collaboration revenue:
Up-front payment associated with the Company's obligation to participate in joint committees	$	736	$	-	$	110	$	-		$	-	$	626

Note 17 - Stock Option Plans (Tables)

9 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

2001 Stock Incentive Plan	Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2015		37,400		$	10.00
Options exercised		(20,400	)		10.00
Options expired		(17,000	)		10.00
Options outstanding, September 30, 2016		-					-	$	-
Options exercisable, September 30, 2016		-					-	$	-
Options vested and expected to vest, September 30, 2016		-					-	$	-

2006 Stock Incentive Plan	Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2015		4,440,608		$	9.37
Options granted		1,266,050			13.60
Options exercised		(280,506	)		5.20
Options forfeited		(90,918	)		13.68
Options expired		(59,365	)		14.53
Options outstanding, September 30, 2016		5,275,869			10.49		8.07	$	14,796,907
Options exercisable, September 30, 2016		2,060,515			8.45		6.96	$	9,134,458
Options vested and expected to vest, September 30, 2016		2,061,303			8.45		6.96	$	9,140,683

2016 Equity Incentive Plan	Shares		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Options outstanding, December 31, 2015		-	$	-
Options granted		41,164		13.55
Options outstanding, September 30, 2016		41,164		13.55		1.12	$	9,926
Options exercisable, September 30, 2016		-		-		-	$	-
Options vested and expected to vest, September 30, 2016		-		-		-	$	-

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

2016 Equity Incentive Plan	Shares		Weighted Average Grant-Date Fair Value
Nonvested Restricted Stock Units, December 31, 2015		-	$	-
Restricted Stock Units granted		63,700		12.29
Restricted Stock Units vested		-
Restricted Stock Units forfeited		-
Nonvested Restricted Stock Units, September 30, 2016		63,700		12.29

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

(In thousands)		Foreign currency translation adjustments		Unrealized income on investments, net of tax effect		Unrealized income (loss) on pension benefit obligation			Accumulated other comprehensive income
Balance January 1, 2016	$	14,243	$	42	$	(873	)	$	13,412
Other comprehensive income before reclassifications		40,890		-		37			40,927
Amounts reclassified from accumulated other comprehensive loss		-		-		-			-
Balance September 30, 2016	$	55,133	$	42	$	(836	)	$	54,339

Note 1 - Business Organization and Basis of Presentation (Details Textual) - USD ($)		1 Months Ended		2 Months Ended	9 Months Ended
	Jan. 01, 2023	Jun. 30, 2015	May 31, 2015	Jun. 30, 2015	Sep. 30, 2016
Takeda [Member] \| Lubiprostone Alternate Formulation [Member]
Additional Reformulation Costs Funded, Percentage					100.00%
Takeda [Member] \| Lubiprostone for Pediatric Functional Constipation [Member]
Additional Reformulation Costs Funded, Percentage					67.00%
Dr. Reddy's Laboratories [Member] \| Scenario, Forecast [Member] \| Generic Lubiprostone [Member]
Sales Agreement, Commission Rate as a Percentage of Gross Sales	30.00%
Gloria [Member] \| China Gloria Agreement [Member]
Collaboration Revenue from Upfront Payment				$ 1,500,000	$ 1,500,000
Gloria [Member] \| First Tranche [Member] \| China Gloria Agreement [Member]
Collaboration Revenue from Upfront Payment			$ 1,000,000
Gloria [Member] \| Second Tranche [Member] \| China Gloria Agreement [Member]
Collaboration Revenue from Upfront Payment		$ 500,000

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Cash, FDIC Insured Amount	$ 1.8		$ 1.8		$ 5.9
Percentage of Deposit within Federally Insured Limits	1.10%		1.10%		3.60%
R-Tech [Member] \| Non-tendering R-tech Shareholders [Member]
Debt Instrument, Covenant, Restricted Cash Account, Balance					$ 8.2
Term Loans [Member] \| Credit Facility [Member]
Debt Instrument, Covenant, Restricted Cash Account, Balance	$ 25.2		$ 25.2		25.0
Debt Instrument Covenant Restricted Cash Account Balance, Threshold	$ 35.0		$ 35.0
Subordinated Unsecured Promissory Notes [Member] \| R-Tech [Member] \| Kuno and Ueno Trust [Member]
Debt Instrument, Covenant, Restricted Cash Account, Balance					$ 17.7
Customer Concentration Risk [Member] \| Sales Revenue, Goods, Net [Member] \| Takeda [Member]
Concentration Risk, Percentage	65.60%	66.30%	65.70%	60.40%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Takeda [Member]
Concentration Risk, Percentage			82.60%		78.10%
Customer Concentration Risk [Member] \| Sales Revenue, Net [Member] \| Mylan [Member]
Concentration Risk, Percentage	29.60%	30.80%	30.10%	36.70%

Note 3 - Net Income Per Share - Computation of Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net income	$ 8,092	$ 7,236	$ 3,203	$ 23,220
Basic net income per share:
Basic (in shares)	42,813	44,731	42,704	44,576
Basic (in dollars per share)	$ 0.19	$ 0.16	$ 0.08	$ 0.52
Diluted net income per share:
Basic (in shares)	42,813	44,731	42,704	44,576
Assumed exercise of stock options under the treasury stock method (in shares)	630	1,578	630	1,363
(in shares)	43,443	46,309	43,334	45,939
Diluted (in dollars per share)	$ 0.19	$ 0.16	$ 0.07	$ 0.51

Note 3 - Net Income Per Share - Potentially Dilutive Securities (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Employee Stock Option [Member]
Employee stock options (in shares)	2,410	273	2,410	884

Note 4 - Acquisition of R-Tech (Details Textual) - R-Tech [Member] - USD ($) $ in Thousands	Dec. 08, 2015	Oct. 20, 2015
Business Acquisition, Percentage of Voting Interests Acquired	2.00%	98.00%
Business Combination, Consideration Transferred	$ 275,000	$ 275,117

Note 4 - Acquisition of R-Tech - Allocation of the Purchase Price of Assets a Acquired and Liabilities Assumed (Details) - USD ($)	Dec. 08, 2015	Oct. 20, 2015	Sep. 30, 2016	Dec. 31, 2015
Goodwill			$ 73,022,000	$ 60,937,000
Squeeze out liability for non-tendering R-Tech shareholders			$ 249,000	$ 7,668,000
R-Tech [Member]
Cash		$ 62,097,000
Accounts receivable		8,299,000
Inventory		37,563,000
Other current assets		3,792,000
Property, plant and equipment		2,796,000
Other long term assets		449,000
Accounts payable and accrued liabilities		(11,598,000)
Income tax payable		(5,025,000)
Other liabilities, current		(3,282,000)
Deferred tax liability, net		(63,365,000)
Other liabilities, long term		(9,347,000)
R-Tech shares of Sucampo stock (treasury stock)		43,956,000
Total fair value of tangible assets acquired and liabilities assumed		66,335,000
Acquired in-process research and development		6,200,000
Acquired intangible assets		134,600,000
Goodwill		61,618,000
Total purchase price		268,753,000
Settlement of net receivable from pre-existing relationship		6,364,000
Total consideration	$ 275,000,000	275,117,000
Acquisition, net of acquired cash		161,187,000
Acquired cash		62,097,000
Squeeze out liability for non-tendering R-Tech shareholders		7,668,000
Other		$ 209,000

Note 4 - Acquisition of R-Tech - Acquisition Pro Forma Information (Details) - R-Tech [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Pro forma revenue	$ 43,529	$ 129,529
Pro forma net income (loss)	$ 1,301	$ (3,036)

Note 5 - Segment Information (Details Textual)	9 Months Ended
Note 5 - Segment Information (Details Textual)	Sep. 30, 2016
Number of Operating Segments	1

Note 5 - Segment Information - Revenues by Product Catergory (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Product royalty revenue	$ 20,771	$ 19,328	$ 56,222	$ 51,209
Product sales revenue	31,554	11,022	86,538	36,678
Research and development revenue	3,172	2,714	9,971	7,468
Contract and collaboration revenue	2,376	384	4,301	2,457
Total	57,873	33,448	157,032	97,812
Product - Amitiza [Member]
Product sales revenue	29,132	10,286	79,253	35,930
Product - Rescula [Member]
Product sales revenue	$ 2,422	$ 736	$ 7,285	$ 748

Note 5 - Segment Information - Revenues by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Total	$ 57,873	$ 33,448	$ 157,032	$ 97,812
UNITED STATES
Total	34,911	22,919	98,073	59,850
JAPAN
Total	19,839	10,295	54,004	35,952
Rest of the World [Member]
Total	$ 3,123	$ 234	$ 4,955	$ 2,010

Note 5 - Segment Information - Long-lived Assets by Geographic Areas (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Long-lived assets	$ 6,563	$ 6,393
UNITED STATES
Long-lived assets	3,192	3,105
JAPAN
Long-lived assets	3,334	3,232
Rest of the World [Member]
Long-lived assets	$ 37	$ 56

Note 6 - Fair Value Measurements (Details Textual) $ in Millions	Sep. 30, 2016 USD ($)
Fair Value, Inputs, Level 3 [Member] \| CPP [Member]
Notes Receivable, Fair Value Disclosure	$ 5.2

Note 7 - Restructuring (Details Textual) $ in Thousands	9 Months Ended
Note 7 - Restructuring (Details Textual) $ in Thousands	Sep. 30, 2016 USD ($)
Restructuring Charges	$ 1,919
Restructuring Reserve	1,000
Restructuring and Related Cost, Cost Incurred to Date	$ 2,900

Note 7 - Restructuring - Restructuring Charges (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Termination benefits	$ 1,809
Asset impairments	86
Contract and other costs	24
Total	$ 1,919

Note 7 - Restructuring - Cash Components of Restructuring Costs (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Expenses incurred	$ 1,919,000
Balance	1,000,000
One-time Termination Benefits [Member]
Balance	851,000	$ 0
Expenses incurred	1,809,000	953,000
Amounts paid	(1,669,000)	(102,000)
Balance	1,005,000	$ 851,000
Foreign currency translation adjustment	$ 14,000

Note 8 - Inventory (Details Textual) - R-Tech [Member] - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Oct. 20, 2015
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			$ 37,563,000
Remaining Portion of Step-Up Measurement [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	$ 0	$ 14,300,000

Note 8 - Inventory - Inventory Components (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Raw materials	$ 2,370	$ 5,554
Work in process	20,380	26,926
Finished goods	1,452	641
Total	$ 24,202	$ 33,121

Note 9 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Note 9 - Intangible Assets (Details Textual) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 7,286,000		$ 7,286,000
In Process Research and Development, before Completion of Development Process [Member]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 7,300,000		$ 7,286,000

Note 9 - Intangible Assets - Intangible Assets by Major Class (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Accumulated amortization	$ (27,382,000)	$ (8,463,000)
Impairment losses	(5,651,000)	(5,651,000)
Foreign currency translation adjustments	22,806,000	(684,000)
Intangible assets	134,886,000	130,315,000
In-process research and development		6,171,000
Goodwill	73,022,000	60,937,000
Total unamortized intangible assets	73,022,000	67,108,000
Total intangible assets	207,908,000	197,423,000
In Process Research and Development, before Completion of Development Process [Member]
In-process research and development	$ 0	$ 6,171,000
Patent and License Rights [Member]
Amortized intangible assets, weighted average life	5 years 90 days	6 years
Amortized intangible assets, carrying amount	$ 10,513,000	$ 10,513,000
Manufacturing Know How [Member]
Amortized intangible assets, weighted average life	5 years 240 days	6 years 120 days
Amortized intangible assets, carrying amount	$ 134,600,000	$ 134,600,000

Note 9 - Intangible Assets - Changes in Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Finite-lived intangible assets, balance			$ 130,315,000
Goodwill, balance			60,937,000
Indefinite-lived intangible assets, balance			6,171,000
Goodwill, additions			455,000
Indefinite-lived intangible assets, impairment	$ (7,286,000)		(7,286,000)
Finite-lived intangible assets, amortization			(18,907,000)
Finite-lived intangible assets, foreign currency translation adjustment			23,478,000
Goodwill, foreign currency translation adjustment			11,630,000
Finite-lived intangible assets, balance	134,886,000		134,886,000
Goodwill, balance	73,022,000		73,022,000
Indefinite-lived intangible assets, balance
In Process Research and Development, before Completion of Development Process [Member]
Indefinite-lived intangible assets, balance			6,171,000
Indefinite-lived intangible assets, impairment	(7,300,000)		(7,286,000)
Indefinite-lived intangible assets, foreign currency translation adjustment			1,115,000
Indefinite-lived intangible assets, balance	$ 0		$ 0

Note 10 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Research and development costs	$ 8,142	$ 3,843
Employee compensation	3,447	4,860
Restructuring	1,005	851
Legal, consulting & other professional expenses	821	428
Other accrued expenses	965	904
Total	14,380	10,886
Indirect taxes payable	3,029	5,963
Squeeze out liability for non-tendering R-Tech shareholders	249	7,668
Deferred revenue	813	676
Other liabilities	714	508
Total	$ 4,805	$ 14,815

Note 11 - Other Liabilities (Details Textual) ¥ in Millions	3 Months Ended	9 Months Ended
Note 11 - Other Liabilities (Details Textual) ¥ in Millions	Sep. 30, 2016 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 JPY (¥)	Dec. 31, 2015 USD ($)	Mar. 31, 2014 JPY (¥)
Gain (Loss) on Forgiveness of Deferred Grant	$ 9,300,000	$ 9,258,000
Deferred Grants, Noncurrrent	750,000	750,000			$ 9,604,000
AMED [Member] \| Unoprostone [Member]
Deferred Grants, Noncurrrent					9,300,000
AMED [Member] \| Unoprostone [Member] \| R-Tech [Member]
Proceeds from Grants Received \| ¥						¥ 1,050
Grant Repayment Amount	$ 1,000,000	$ 1,000,000		¥ 105
Grant Repayment Amount as Percentage of Grants Received	10.00%	10.00%		10.00%
Montgomery County Government [Member] \| Montgomery County, Maryland [Member]
Deferred Grants, Noncurrrent					$ 300,000

Note 11 - Other Liabilities - Summary of Other Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Deferred grants	$ 750	$ 9,604
Unrecognized tax benefits	3,694	3,061
Deferred leasehold incentive	1,618	1,715
Defined benefit obligation	972	949
Other liabilities	1,257	414
Total	$ 8,291	$ 15,743

Note 12 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating Leases, Rent Expense	$ 650,000	$ 482,000	$ 2,000,000	$ 1,100,000

Note 12 - Commitments and Contingencies - Future Minimum, Non-Cancelable Lease Payments (Details) $ in Thousands	Sep. 30, 2016 USD ($)
2016	$ 576
2017	1,186
2018	1,323
2019	1,048
2020	974
2021	3,188
Total minimum lease payments	$ 8,295

Note 13 - Related Party Transactions (Details Textual) SFr in Millions		3 Months Ended	9 Months Ended	12 Months Ended	154 Months Ended
	Dec. 01, 2015	Sep. 30, 2015 USD ($)	Sep. 30, 2015 USD ($)	Dec. 31, 2010 USD ($)	Oct. 20, 2015 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2015 CHF (SFr)	Sep. 30, 2011 CHF (SFr)
Related Party Transaction, Amounts of Transaction					$ 9,000,000
R-Tech [Member]
Related Party Transaction, Other Revenues from Transactions with Related Party		$ 356,000	$ 829,000
Numab [Member]
Long-term Debt, Gross						$ 1,500,000	SFr 1.5
Numab [Member] \| Financial Guarantee [Member]
Restricted Cash and Cash Equivalents \| SFr							2.2
Guaranty Liabilities						202,000
Numab [Member] \| Zurcher Kantonalbank [Member]
Loans Pledged as Collateral						$ 2,200,000	SFr 2.2	SFr 5.0
Ueno Trust [Member] \| SAG [Member] \| Subordinated Unsecured Promissory Notes [Member]
Debt Instrument, Face Amount				$ 25,900,000
Kuno and Ueno Trust [Member] \| SAG [Member] \| Subordinated Unsecured Promissory Notes [Member]
Debt Instrument, Face Amount				$ 51,900,000
Kuno and Ueno Trust [Member] \| SAG [Member] \| Subordinated Unsecured Promissory Notes [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	4.70%			4.00%

Note 13 - Related Party Transactions - Expenses Under Agreements With R-Tech (Details) - R-Tech [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Expenses related to R-Tech	$ 5,224	$ 18,528
Clinical Supplies [Member]
Expenses related to R-Tech	106	143
Other Research and Development Services [Member]
Expenses related to R-Tech	258	347
Commercial Supplies [Member]
Expenses related to R-Tech	$ 4,860	$ 18,038

Note 14 - Credit Facility and Notes Payable (Details Textual) - Jeffries Financing LLC [Member] - Term Loans [Member]		9 Months Ended
	Oct. 16, 2015	Sep. 30, 2016
Debt Instrument, Interest Rate During Period	6.25%	8.43%
Adjusted Eurodollar [Member]
Debt Instrument, Basis Spread on Variable Rate	7.25%

Note 15 - Collaboration Obligation (Details Textual) - Global License Agreement [Member] - Takeda [Member] - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Development Expenses to Be Assumed			$ 6.0
Developmental Expense Reimbursement Obligation	$ 1.4	$ 5.6
Up-front Payment Arrangement [Member]
Deferred Revenue			$ 14.0

Note 16 - Collaboration and License Agreements (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Sales Revenue, Goods, Net	$ 31,554	$ 11,022	$ 86,538	$ 36,678
Santen [Member] \| Japan Santen Agreement [Member] \| RESCULA [Member]
Sales Revenue, Goods, Net	$ 2,300		$ 7,100

Note 16 - Collaboration and License Agreements - Cash Streams and Related Revenue Recognized or Deferred Under the North American Takeda Agreement (Details) - Takeda [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Product Royalty Revenue [Member]
Amount Deferred
Cash Received	58,027
Revenue Recognized	56,005
Accounts Receivable	(2,022)
Foreign Currency Effects
Product Sales Revenue [Member]
Amount Deferred
Cash Received	34,382
Revenue Recognized	31,953
Accounts Receivable	(501)
Foreign Currency Effects	(1,928)
Research and Development Revenue [Member] \| Reimbursement of Research and Development Expenses [Member]
Amount Deferred
Cash Received	9,378
Revenue Recognized	9,964
Accounts Receivable	586
Foreign Currency Effects
Collaboration Revenue [Member] \| Up-front Payment Arrangement [Member]
Amount Deferred	626	$ 736
Cash Received
Revenue Recognized	110
Accounts Receivable
Foreign Currency Effects

Note 16 - Collaboration and License Agreements - Cash Streams and Related Revenue Recognized or Deferred Under the Japan Mylan Agreement (Details) - Mylan [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Product Sales Revenue [Member]
Amount Deferred
Cash Received	49,276
Revenue Recognized	46,509
Accounts Receivable	2,122
Foreign Currency Effects	(4,889)
Collaboration Revenue [Member] \| Up-front Payment Arrangement [Member]
Amount Deferred	482	$ 416
Cash Received
Revenue Recognized	29
Accounts Receivable
Foreign Currency Effects	$ 95

Note 17 - Stock Option Plans (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 7.10		$ 9.45
Stock Issued During Period, Value, Employee Stock Purchase Plan			$ 174,000
Stock Incentive Plan 2006 [Member] \| Common Class A [Member]
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 46,262	$ 36,324	$ 174,572	$ 74,414
Stock Issued During Period, Shares, Employee Stock Purchase Plans	4,932	2,502	18,719	5,442

Note 17 - Stock Option Plans - Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2016 USD ($) $ / shares shares
Amended 2001 Plan [Member]
Options outstanding, shares (in shares) \| shares	37,400
Options outstanding, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 10
Options exercised, shares (in shares) \| shares	(20,400)
Options exercised, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 10
Options expired, shares (in shares) \| shares	(17,000)
Options expired, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 10
Options outstanding, shares (in shares) \| shares
Options outstanding, weighted average exercise price per share (in dollars per share) \| $ / shares
Options outstanding, weighted average remaining contractual term
Options outstanding, aggregate intrinsic value \| $
Options exercisable, shares (in shares) \| shares
Options exercisable, weighted average remaining contractual term
Options exercisable, aggregate intrinsic value \| $
Options vested and expected to vest, shares (in shares) \| shares
Options vested and expected to vest, weighted average remaining contractual term
Options vested and expected to vest, aggregate intrinsic value \| $
Options exercised, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 10
Stock Incentive Plan 2006 [Member]
Options outstanding, shares (in shares) \| shares	4,440,608
Options outstanding, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 9.37
Options exercised, shares (in shares) \| shares	(280,506)
Options exercised, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 5.20
Options expired, shares (in shares) \| shares	(59,365)
Options expired, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 14.53
Options outstanding, shares (in shares) \| shares	5,275,869
Options outstanding, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 10.49
Options outstanding, weighted average remaining contractual term	8 years 25 days
Options outstanding, aggregate intrinsic value \| $	$ 14,796,907
Options exercisable, shares (in shares) \| shares	2,060,515
Options exercisable, weighted average remaining contractual term	6 years 350 days
Options exercisable, aggregate intrinsic value \| $	$ 9,134,458
Options vested and expected to vest, shares (in shares) \| shares	2,061,303
Options vested and expected to vest, weighted average remaining contractual term	6 years 350 days
Options vested and expected to vest, aggregate intrinsic value \| $	$ 9,140,683
Options granted, shares (in shares) \| shares	1,266,050
Options granted, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 13.60
Options exercised, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 5.20
Options forfeited, shares (in shares) \| shares	(90,918)
Options forfeited, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 13.16
Options exercisable, weighted average exercise price per share (in dollars per share) \| $ / shares	8.45
Options vested and expected to vest, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 8.45
Stock Incentive Plan 2016 [Member]
Options outstanding, shares (in shares) \| shares
Options outstanding, weighted average exercise price per share (in dollars per share) \| $ / shares
Options outstanding, shares (in shares) \| shares	41,164
Options outstanding, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 13.55
Options outstanding, weighted average remaining contractual term	1 year 43 days
Options outstanding, aggregate intrinsic value \| $	$ 9,926
Options exercisable, shares (in shares) \| shares
Options exercisable, weighted average remaining contractual term
Options exercisable, aggregate intrinsic value \| $
Options vested and expected to vest, shares (in shares) \| shares
Options vested and expected to vest, weighted average remaining contractual term
Options vested and expected to vest, aggregate intrinsic value \| $
Options granted, shares (in shares) \| shares	41,164
Options granted, weighted average exercise price per share (in dollars per share) \| $ / shares	$ 13.55
Options exercisable, weighted average exercise price per share (in dollars per share) \| $ / shares
Options vested and expected to vest, weighted average exercise price per share (in dollars per share) \| $ / shares

Note 17 - Stock Option Plans - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2016 $ / shares shares
Nonvested Restricted Stock Units, shares (in shares) \| shares
Nonvested Restricted Stock Units, weighted average fair value (in dollars per share) \| $ / shares
Restricted Stock Units granted, shares (in shares) \| shares	63,700
Restricted Stock Units granted, weighted average fair value (in dollars per share) \| $ / shares	$ 12.29
Restricted Stock Units vested, shares (in shares) \| shares
Restricted Stock Units vested, weighted average fair value (in dollars per share) \| $ / shares
Restricted Stock Units forfeited, shares (in shares) \| shares
Restricted Stock Units forfeited, weighted average fair value (in dollars per share) \| $ / shares
Nonvested Restricted Stock Units, shares (in shares) \| shares	63,700
Nonvested Restricted Stock Units, weighted average fair value (in dollars per share) \| $ / shares	$ 12.29

Note 17 - Stock Option Plans - Changes in Accumulated Other Comprehensive Income (Loss) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Balance	$ 13,412
Other comprehensive income before reclassifications	40,927
Balance	54,339
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	14,243
Other comprehensive income before reclassifications	40,890
Balance	55,133
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
Balance	42
Other comprehensive income before reclassifications
Balance	42
Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]
Balance	(873)
Other comprehensive income before reclassifications	37
Balance	$ (836)

Note 18 - Income Taxes (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Effective Income Tax Rate Reconciliation, Percent	47.80%	37.40%	57.40%	32.10%
Unrecognized Tax Benefits	$ 3.7		$ 3.7
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 1.8		$ 1.8
Latest Tax Year [Member]
Open Tax Year			2015
Earliest Tax Year [Member]
Open Tax Year			2011
Minimum [Member]
Effective Income Tax Rate Reconciliation, Percent			0.00%
Maximum [Member]
Effective Income Tax Rate Reconciliation, Percent			40.00%

Note 19 - Investment in CPP (Details Textual) - USD ($)		1 Months Ended	3 Months Ended	9 Months Ended
Note 19 - Investment in CPP (Details Textual) - USD ($)	Jan. 09, 2016	Jan. 31, 2016	Sep. 30, 2016	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Assets			$ 459,564,000	$ 459,564,000		$ 457,181,000
Liabilities			314,754,000	314,754,000		$ 370,732,000
Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage	5.00%
CPP [Member]
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount			5,200,000	5,200,000
Collaboration Agreement, Amount of Investment	$ 5,000,000
Assets					$ 7,100,000
Liabilities					$ 20,500,000
Collaboration Agreement, Minimum Aggregate Proceeds Contingent on Consummation of Future Financing	10,000,000
Collaboration Agreement, Amount of Equity Investment	5,000,000
Option Fee, Maximum	$ 7,500,000
Number of Tranches	2
Payment of Option Fee		$ 3,000,000	4,500,000
Maximum Aggregate License Fees and Milestone Payments				190,000,000
CPP [Member] \| IPO [Member] \| Minimum [Member]
Collaboration Agreement, Discount under Qualified Financing	10.00%
CPP [Member] \| IPO [Member] \| Maximum [Member]
Collaboration Agreement, Discount under Qualified Financing	20.00%
CPP [Member] \| Fair Value, Inputs, Level 3 [Member]
Notes Receivable, Fair Value Disclosure			$ 5,200,000	$ 5,200,000

Note 17 - Stock Option Plans - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2016 $ / shares shares
Nonvested Restricted Stock Units, shares (in shares) \| shares
Nonvested Restricted Stock Units, weighted average fair value (in dollars per share) \| $ / shares
Restricted Stock Units granted, shares (in shares) \| shares	63,700
Restricted Stock Units granted, weighted average fair value (in dollars per share) \| $ / shares	$ 12.29
Restricted Stock Units vested, shares (in shares) \| shares
Restricted Stock Units vested, weighted average fair value (in dollars per share) \| $ / shares
Restricted Stock Units forfeited, shares (in shares) \| shares
Restricted Stock Units forfeited, weighted average fair value (in dollars per share) \| $ / shares
Nonvested Restricted Stock Units, shares (in shares) \| shares	63,700
Nonvested Restricted Stock Units, weighted average fair value (in dollars per share) \| $ / shares	$ 12.29